



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 31/00</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/54762</b> (43) International Publication Date: 21 September 2000 (21.09.00)												
<p>(21) International Application Number: PCT/US00/06819</p> <p>(22) International Filing Date: 15 March 2000 (15.03.00)</p> <p>(30) Priority Data: 60/124,703 15 March 1999 (15.03.99) US</p> <p>(71) Applicant (for all designated States except US): TRUSTEES OF BOSTON UNIVERSITY [US/US]; 147 Bay State Road, Boston, MA 02215 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): MOULTON, Steven [US/US]; 217 Westerly Road, Weston, MA 02193 (US).</p> <p>(74) Agent: GOSZ, William, G.; Wolf, Greenfield &amp; Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>												
<p>(54) Title: ANGIOGENESIS INHIBITION</p> <p>(57) Abstract</p> <p>Angiogenesis is inhibited by the local administration of a pharmaceutical preparation formed from the reaction of hyaluronic acid, carboxymethylcellulose and a carbodiimide. The preparation, which can be in the form of a film or a gel, is advantageously applied directly to the site of a tumor, such as a cancerous tumor, used in conjunction with other chemotherapeutic techniques, or used to treat a chronic inflammatory condition, such as rheumatoid arthritis, endometriosis, arteriosclerosis, intimal hyperplasia, proliferative retinopathy, and the like.</p> <div data-bbox="897 1559 1825 2201"> <p style="text-align: center;"><b>% Vessel Coverage Over Silastic</b></p> <table border="1"> <caption>% Vessel Coverage Over Silastic Data</caption> <thead> <tr> <th>Post-surgery Days</th> <th>Controls (%)</th> <th>Seprafilm (%)</th> </tr> </thead> <tbody> <tr> <td>10</td> <td>~60</td> <td>~25</td> </tr> <tr> <td>15</td> <td>~80</td> <td>~65</td> </tr> <tr> <td>35</td> <td>~85</td> <td>~75</td> </tr> </tbody> </table> </div> <p style="text-align: center;">Day 10, P = .02 Day 15, P = .09 Day 35, P = 0.15</p>			Post-surgery Days	Controls (%)	Seprafilm (%)	10	~60	~25	15	~80	~65	35	~85	~75
Post-surgery Days	Controls (%)	Seprafilm (%)												
10	~60	~25												
15	~80	~65												
35	~85	~75												

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANGIOGENESIS INHIBITION

## BACKGROUND OF THE INVENTION

5 This invention relates to methods for inhibiting angiogenesis in a mammal by the local administration of an activated hyaluronic acid composition to the site where the anti-angiogenesis effect is desired. The anti-angiogenesis method of this invention can be used to control or inhibit solid tumor growth in cancer patients, to modulate wound healing, and to prevent or reduce inflammation.

10 Vasculogenesis is a necessary process in the establishment of embryonic tissue whereby endothelial cells are born from progenitor cell types. In contrast, angiogenesis is a process wherein new capillaries sprout from existing vessels. Thus, angiogenesis is necessary for the establishment and development of tumor tissue, as well as the control of certain inflammatory conditions. Angiogenesis is also known to play an integral role in wound  
15 healing by allowing tissue generation and remodeling. The inhibition of angiogenesis can be a useful tool for the control of wound healing, inflammation and solid tumor growth.

Angiogenesis-dependent diseases are those diseases which require or induce vascular growth. Such diseases represent a significant portion of all diseases for which medical treatment is sought, and include cancers and inflammatory arthritis.

20 Standard approaches for the treatment and management of cancer involve the use of surgical procedures to excise the tumor, followed by the use of chemotherapeutic drugs and/or radiation treatment to prevent a reoccurrence of the cancer. The chemotherapeutic drugs, such as cisplatin and methotrexate, are typically introduced directly into the patient's blood stream and carried to the site of the tumor. There is now evidence, however, that tumors actually  
25 compress their blood supply, making it difficult for the drug to reach the target cancer cells. In order to reach the cancer cells, the drugs must cross the blood-vessel wall and the interstitial spaces within the tumor. An alternative approach is to develop drugs which will inhibit the growth of blood vessels within the tumor.

U.S. Patent No. 4,771,042 discloses steroid compositions which are useful for  
30 inhibiting angiogenesis. These compositions are administered intramuscularly, intravenously or orally, and are useful for treating various traumas, cancer and infertility.

U.S. Patent No. 5,001,116 describes the inhibition of angiogenesis by the co-administration of heparin and steroids. The patent discloses that neither the steroids nor heparin alone have any anti-angiogenic activity, and it is the combination of the two which is unexpectedly effective for this purpose. The routes of administration are parenteral or oral. 5 and the compositions are disclosed as being particularly useful for tumor regression or to prevent metastasis.

Hyaluronic acid ("HA") is a naturally occurring mucopolysaccharide found, for example, in synovial fluid, in vitreous humor, in blood vessel walls and the umbilical cord, and in other connective tissues. The polysaccharide consists of alternating N-acetyl-D-glucosamine and D-glucuronic acid residues joined by alternating  $\beta$ 1-3 glucuronicidic and  $\beta$ 1-4 glucosaminidic bonds, so that the repeating unit is  $-(1 \rightarrow 4)\text{-}\beta\text{-D-GlcA}\text{-(}1 \rightarrow 3\text{)-}\beta\text{-D-GlcNAc-}$ . 10 In water, hyaluronic acid dissolves to form a highly viscous fluid. The molecular weight of hyaluronic acid isolated from natural sources generally falls within the range of  $5 \times 10^4$  up to  $1 \times 10^7$  daltons.

15 Hyaluronic acid, in chemically modified ("derivatized") or crosslinked form, is useful as a surgical aid to prevent adhesions or accretions of body tissues during the post-operative period. The derivatized or crosslinked HA gel or film is injected or inserted into the locus between the tissues that are to be kept separate to inhibit their mutual adhesion. Chemically modified or crosslinked HA can also be useful for controlled release drug delivery. See U.S. 20 Patent No. 4,937,270 and U.S. Patent No. 5,017,229 which disclose derivatized versions of HA, or HA in combination with other polyanionic polysaccharides such as carboxymethylcellulose, which can be prepared by reacting the HA with a carbodiimide. U.S. Patent No. 4,582,865, and pending U.S. Application Serial No. 09/503,544, filed February 14, 2000, each describe the reaction of hyaluronic acid with divinyl sulfone, and the use of these 25 products in medical applications.

A derivatized version of HA and carboxymethylcellulose ("CMC"), in combination, is available commercially as Seprafilm™ membranes and films from the Genzyme Corporation. CMC is an anionic polysaccharide and a derivatized form of cellulose in which the glucosidic hydroxyl groups have been carboxymethylated, thereby rendering the polymer water soluble. 30 This derivative of HA and CMC can be prepared by mixing HA with CMC and an activating agent to form a water insoluble precipitate. The precipitate is cast into a thin film membrane.

which can be implanted into the peritoneal cavity or other sites to prevent the formation of post-operative adhesions.

I. Danishefsky et al., *Carbohydrate Res.*, Vol. 16, pages 199-205, 1971, describe modifying a mucopolysaccharide by converting the carboxyl groups of the  
5 mucopolysaccharide into substituted amides by reacting the mucopolysaccharide with an amino acid ester in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride ("EDC") in aqueous solution. Danishefsky et al. react glycine methyl ester with a variety of polysaccharides, including HA. The resulting products are water soluble; that is, they rapidly disperse in water or in an aqueous environment such as is encountered  
10 between body tissues.

U.S. Patent No. 5,847,002 describes a method for inhibiting, controlling or regressing angiogenesis by administering to a subject a non-steroidal anti-inflammatory agent ("NSAID") and hyaluronic acid ("HA"). The function of the NSAID is to decrease the production of inflammatory mediators, many of which are pro-angiogenic, thereby inhibiting  
15 granuloma formation. The patent states that the NSAID and HA act synergistically as an angiostatic agent.

U.S. Patent No. 5,902,795 discloses the use of hyaluronan oligosaccharides and antibodies to hyaluronan binding proteins to treat tumors or other diseases which can be linked to angiogenesis. The compositions of this patent block the hyaluronan binding protein  
20 on the cell surface during tumor cell and endothelial cell migration, and during capillary-like tubule formation.

U.S. Patent No. 6,022,866 describes the use of solutions of hyaluronic acid to prevent arterial restinosis. The hyaluronic acid solution is administered to a patient to prevent the narrowing of the tubular walls of an artery after being traumatized, such as the narrowing  
25 which can occur following a balloon angioplasty procedure.

It will be appreciated that there is a need for an improved anti-angiogenesis formulation and therapeutic treatments which use such formulations.

### SUMMARY OF THE INVENTION

30 In general terms, the present invention features a method for inhibiting angiogenesis in a mammal by the local administration of an activated hyaluronic acid composition to the site where the anti-angiogenesis result is desired. The anti-angiogenesis method of this invention

can be used to control or inhibit solid tumor growth in cancer patients. to modulate wound healing. and to prevent or reduce inflammation and inflammatory diseases.

In one aspect. the activated polyanionic polysaccharide is formed by reacting the polyanionic polysaccharide with a carbodiimide in an aqueous medium under suitable reaction  
5 conditions. The preferred pH for carrying out the reaction is 3.5 to 8.0. The preferred concentration for the polyanionic polysaccharide is from about 0.005 to 0.1M. more preferably from about 0.01 to 0.02M. The molar ratio of the polyanionic polysaccharide to activating agent is preferably at least 1:1. and more preferably about 1:4. The preferred carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or  
10 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide methiodide.

In a further aspect. the crosslinked polyanionic polysaccharide compositions are prepared by reacting the polyanionic polysaccharide with a suitable crosslinking agent. such as divinyl sulfone. in a solvent under suitable reaction conditions.

In another aspect. the anti-angiogenesis compositions of this invention are used in a  
15 therapeutic method for the treatment of solid cancerous tumors and surrounding tissue. The compositions of this invention can be used alone. or in combination with other anti-angiogenic compositions. such as steroids. which can be administered to the site of the cancerous tumor. The pharmaceutical preparations can also include other pharmaceutically active substances dispersed throughout. making the preparations useful as drug delivery  
20 vehicles. Suitable pharmaceutically active substances include proteins. such as growth factors. soluble receptors and enzymes. drugs. antibodies. biopolymers. and biologically compatible synthetic polymers.

In a further aspect. this invention encompasses a method for the treatment of non-tumorigenic. angiogenesis-dependent diseases by the administration of the present  
25 compositions to the site of the inflammation to inhibit the formation of new blood vessels. Preferred angiogenesis-dependent diseases which may be treated by the compositions of this invention include. for instance. inflammatory arthritis. such as rheumatoid arthritis.

Unless defined otherwise. all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention  
30 belongs. Although any method and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. the preferred methods and materials are now described. All publications mentioned hereunder. including published

patent applications, and issued or granted patents, are incorporated by reference in their entirety. Unless mentioned otherwise, the techniques employed or contemplated herein are standard methodologies well known to one of ordinary skill in the art. The materials, methods and examples are illustrative only and not intended to be limiting.

5 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments, and from the claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a bar graph illustrating the adhesion scores for Seprafilm treated and control  
10 animals at 10, 15 and 35 days following surgery.

FIG. 2 is a bar graph illustrating the incidence of adhesions for Seprafilm treated and control animals at 10, 15 and 35 days following surgery.

FIG. 3 is a bar graph illustrating the area of vessel coverage over a silastic patch for Seprafilm treated and control animals at 10, 15 and 35 days following surgery.

15

### DETAILED DESCRIPTION

The pharmaceutical compositions of this invention are prepared by reacting a polyanionic polysaccharide, such as hyaluronic acid or carboxymethylcellulose, with a suitable activating agent, such as a carbodiimide. Preparations of this type are well known in the art, and are disclosed, for instance, in U.S. Patent No. 5,017,229, the disclosure of which is incorporated by reference herein.  
20

As used herein, and unless otherwise indicated, the terms "HA" and "hyaluronic acid" denote hyaluronic acid and any of its hyaluronate salts, including, for example, sodium hyaluronate (the sodium salt), potassium hyaluronate, magnesium hyaluronate, and calcium  
25 hyaluronate. The term "polyanionic polysaccharide" means hyaluronic acid (HA), carboxymethylcellulose ("CMC"), carboxymethylamylose ("CMA"), chondroitin sulfate, dermatin sulfate, heparin, and heparin sulfate.

The term "CMC and "carboxymethylcellulose" refer to the carboxymethyl derivatized form of cellulose in which the glucosidic hydroxyl groups have been carboxymethylated to  
30 render the polymer water soluble, as well as substituted and modified versions of the molecule.

"Angiogenesis", as used herein, refers to the formation of new blood vessels from pre-existing blood vessels. Angiogenesis is turned on and off by the upregulated expression of angiogenic growth factors or by angiogenesis inhibitors. Angiogenesis is thought to play an integral role in wound healing since tissue generation and remodeling can only occur when  
5 accompanied by blood vessel formation.

"Local administration" means contacting the pharmaceutical preparation with tissue surfaces in the immediate proximity to the tumor in the body where the anti-angiogenesis effect is desired. The preparation may be in the form of a film or gel. The film or gel may be inserted into the site of the trauma or cancer by an attending physician. A convenient method  
10 for local administration, particularly in the case of a gel formulation, is the use of a minimally invasive surgical procedure for installing the product.

A "gel" is a substance having a consistency which varies from a solid or semi-solid to a liquid. A "film" is a thin flexible sheet or membrane which can readily be folded and manipulated to conform to a desired shape. A film can be a gel product which has  
15 substantially all of the moisture removed therefrom.

An "activating agent" is a substance that, in an aqueous mixture including hyaluronic acid, renders the carboxyl groups on the hyaluronic acid vulnerable to nucleophilic attack.

An "acyl derivative," as that term may be used herein, is a compound produced by the displacement of the hydroxyl group bound to the acyl carbon atom of a carboxylic acid moiety  
20 by either the reaction of the hydroxyl group with a nucleophilic group of another compound, or by the rearrangement of the O-acylisourea formed by reaction of the hydroxyl group with a carbodiimide. Examples of acyl derivatives include acylureas, acylisoureas, amides, thioesters, and phenolates.

A "mammal" shall mean a human or non-human mammal, including but not limited  
25 to, a dog, cat, horse, cow, pig, sheep, goat, chicken, primate, rat, and mouse.

The activated polyanionic polysaccharide of this invention can be prepared by treating a polyanionic polysaccharide with a suitable carbodiimide in the presence or absence of a nucleophile. Preferably, the polyanionic polysaccharide is hyaluronic acid. The resulting product may be water soluble or water insoluble, depending on the reaction conditions and the  
30 relative proportions of ingredients in the reaction mixture. The reaction of the carbodiimide with the carboxyl group of the hyaluronic acid proceeds through the addition of the free carboxylate to one of the double bonds of the diimide to give the O-acylisourea derivatives of

the hyaluronic acid and the carbodiimide. In the presence of a nucleophile, such as a primary amine, the amide derivative of the hyaluronic acid forms as well as the unimolecular O→N rearrangement of the O-acylisourea derivatives to give the more stable N-acylurea derivatives of the hyaluronic acid and the carbodiimide. In the absence of a nucleophile, the

5 intramolecular rearrangement from the O-acylisourea derivatives to the N-acylurea derivatives is the predominant reaction.

The hyaluronic acid, or a salt of hyaluronic acid, such as sodium hyaluronate, is dissolved in water to make an aqueous mixture. HA from any of a variety of sources can be used. As is well known to those skilled in the art, HA can be extracted from animal tissues or

10 harvested as a product of bacterial fermentation. Hyaluronic acid can be produced in commercial quantities by bioprocess technology, as described for example in PCT Publication No. WO 86/04355. Preferably the concentration of HA in this first aqueous mixture is in the range between 0.05% to 2.0% weight/weight ("w/w"), and more preferably 0.1% to 1%. Subsequent reactions are slower and less effective at significantly lower concentrations, while

15 significantly higher concentrations are difficult to handle owing to their high viscosity. The aqueous HA mixture should be acidic, preferably having a pH between pH 3.5 and pH 8.0. At lower pH values the preferred activating agent, EDC, is unstable, and at higher values the reaction rate is diminished. Preferably hydrochloric acid is added to adjust the pH, although other known acids can be used.

20 Once the pH of the aqueous HA mixture has been adjusted, a carbodiimide is admixed with the HA. Preferred carbodiimides include EDC (in some references this substance is termed 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide or "DEC") or ETC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide methiodide).

The mode of addition of the reagents is not critical, but the ratio of the carbodiimide to

25 HA is important. Lower ratios typically form weaker, less insoluble products, while higher ratios typically result in stronger, more insoluble products. It is generally advantageous to have a more insoluble product since the substrate can be thoroughly washed with water without appreciable deterioration.

The pharmaceutical preparations of this invention are preferably administered locally

30 to the site of the trauma, inflammation or cancer. They can be used in conjunction with other therapies, such as chemotherapy for treating solid cancerous tumors or tissue, and they can be used in combination with other anti-angiogenesis products and compositions.

For the treatment of cancer, the compositions of this invention can be used to coat an area prior to or after the removal of a solid tumor. The compositions may also be delivered by endoscopic procedures to coat the tumor and/or the surrounding area, or to inhibit angiogenesis in the desired area. The compositions of this invention can also be used to treat tumor excision sites. The types of tumors which may be treated in this manner include colon tumors, breast tumors, brain tumors, and hepatic tumors, among others.

The compositions can also be used to treat inflammatory arthritis, such as rheumatoid arthritis, by administering the compositions to a joint, for example. Other angiogenesis-dependent diseases which may be treated in accordance with the methods of this invention include psoriasis, pyogenic granuloma, scleroderma, trachoma, endometriosis, arteriosclerosis, intimal hyperplasia, proliferative retinopathy, and the like.

Treatment methods which can be advantageously used in the practice of this invention include those disclosed in U.S. Patent No. 5,994,341, the disclosure of which is incorporated by reference herein in its entirety.

The present invention provides pharmaceutical compositions, for medical use, which in some aspects comprise the anti-angiogenesis compositions of the invention together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. Thus the invention also relates to anti-angiogenesis pharmaceutical compositions in combination with an anti-infectious agent such as an antibacterial or anti-viral agent, an anti-inflammatory agent, or other therapeutic agent and a pharmaceutically acceptable carrier. The pharmaceutical compositions useful in the invention may be delivered separately with the other therapeutic agent or in the form of therapeutic cocktails. A therapeutic cocktail is a mixture of any pharmaceutical composition of the invention and another therapeutic agent. In this embodiment, a common administration vehicle could contain both the pharmaceutical composition and the other therapeutic agent. Alternatively, the other therapeutic agent can be separately dosed.

The precise amounts of the therapeutic agent used in combination with the pharmaceutical compositions of the invention will depend upon a variety of factors, including the pharmaceutical composition selected, the dose and dose-timing selected, the mode of administration, the nature of any surgical or medical procedure contemplated and the characteristics of the subject. Where local administration is carried out, it will be understood that very small amounts may be required (nanograms and possibly picograms). The precise

amounts selected can be determined without undue experimentation, particularly since a threshold amount will be any amount which will favorably enhance the desired response. Thus, it is believed that picogram to milligram amounts are possible, depending upon the mode of delivery, but that nanogram to microgram amounts are likely to be most useful.

5 Multiple doses of the pharmaceutical compositions of the invention are contemplated. For instance, when being administered in conjunction with a surgical procedure the compounds of the invention can be administered in multiple doses over a three week period preceding surgery, over a two week period preceding surgery, over a one week period preceding surgery, over a one day period preceding surgery, etc. Further doses may be  
10 administered post surgery as well. Any regimen that prevents an inflammatory response may be used, although optimum doses and dosing regimens are those that would not only inhibit the development of cancer or the inflammatory disease, but also would prevent the reoccurrence of cancer or the inflammatory disease. Desired time intervals for delivery of multiple doses of a particular pharmaceutical composition can be determined by one of  
15 ordinary skill in the art employing no more than routine experimentation.

The formulations of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

20 The pharmaceutical composition may be administered per se (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric,  
25 nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a  
30 salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

The pharmaceutical compositions of the invention contain an effective amount of a pharmaceutical composition optionally included in a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" means one or more compatible solid or liquid filler, dilutants or encapsulating substances which are suitable for administration to a human or other mammals. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the pharmaceutical compositions of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.

The pharmaceutical compositions useful in the invention may be delivered in mixtures of more than one pharmaceutical composition. A mixture may consist of several pharmaceutical compositions.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular pharmaceutical composition selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the anti-angiogenesis response without causing clinically unacceptable adverse effects. Preferred modes of administration include, e.g., deposition, implantation, and topical administration.

In certain preferred embodiments of the invention, the administration can be designed so as to result in sequential exposure of the pharmaceutical composition over some period of time, e.g., hours, days, weeks, months or years. This can be accomplished by repeated administrations of the pharmaceutical composition, by one of the methods described above, or alternatively, by a sustained-release delivery system in which the pharmaceutical composition is delivered to the subject for a prolonged period without repeated administrations. By sustained-release delivery system, it is meant that total release of the pharmaceutical composition does not occur immediately upon administration, but rather is delayed for some period of time.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the pharmaceutical composition into association with a carrier which

constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the pharmaceutical composition into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

5       The pharmaceutical compositions are administered to the mammal in a therapeutically-effective amount. By therapeutically-effective amount it is meant that amount which is capable of at least partially preventing, reversing, reducing, decreasing, ameliorating, or otherwise suppressing the inflammatory response being treated. A therapeutically-effective amount can be determined on an individual basis and will be based, at least in part, on  
10   consideration of the species of mammal, the mammal's age, sex, size, and health; the type of pharmaceutical composition used; the type of delivery system used; the time of administration relative to the severity of the disease; and whether a single, multiple, or controlled-release dose regimen is employed. A therapeutically-effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine  
15   experimentation.

In some embodiments, the concentration of the pharmaceutical composition if administered systemically is at a dose of about 1.0 mg to about 2000 mg for an adult of 70 kg body weight, per day. In other embodiments, the dose is about 10 mg to about 1000 mg/70 kg/day. In yet other embodiments, the dose is about 100 mg to about 500 mg/70 kg/day.  
20   Preferably, the concentration of the pharmaceutical composition, if applied topically, is about 0.1 mg to about 500 mg/gm of gels or other base, more preferably about 1.0 mg to about 100 mg/gm of base, and most preferably, about 30 mg to about 70 mg/gm of base. The specific concentration partially depends upon the particular pharmaceutical composition used, as some are more effective than others. The dosage concentration of the pharmaceutical composition  
25   actually administered is dependent at least in part upon the particular disorder being treated, the final concentration of pharmaceutical composition that is desired at the site of action, the method of administration, the efficacy of the particular pharmaceutical composition, the longevity of the particular pharmaceutical composition, and the timing of administration relative to the severity of the disease. Preferably, the dosage form is such that it does not  
30   substantially deleteriously effect the mammal. The dosage can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.

Without wishing to be bound by any particular theory or mechanism of action, it is believed that the early reduction in vessel growth due to the anti-angiogenic effect of the instant preparations also contributes to long term adhesion reduction. Intraabdominal adhesions begin as fibrinous adhesions, which are transient and may be completely lysed within 72 hours if the fibrinolytic system is active and there is no underlying tissue ischemia. If the fibrinolytic system is depressed, foreign material remains or there is persistent tissue ischemia, the fibrinous adhesions persist. They are thought to play a principal role in peritoneal or mesothelial wound healing by providing a scaffolding for the ingrowth of new blood vessels, i.e. angiogenesis, the delivery of cellular elements, and the subsequent proliferation of fibroblasts. Wound healing in this setting is characterized by a variety of redundant, overlapping and sequential processes involving a wide variety of cytokines, chemoattractants, mitogens, growth factors, and cellular mediators. During this process, the cells in the developing adhesion differentiate and synthesize extracellular matrix to form a fibrous adhesion. Accordingly, these fibrous adhesions are precursors in the development of mature intraabdominal adhesions.

It is also believed that angiogenesis plays a significant role in the inflammatory process. In acute inflammation, the endothelium regenerates to replace injured or dying endothelial cells, but new capillaries are not formed. In contrast, the principal vascular response in chronic inflammation is neovascularization. This is the type of inflammatory response that is elicited in juvenile rheumatoid arthritis, arteriosclerosis, and proliferative retinopathy. Chronic inflammation can also follow a surgical injury or the placement of a foreign object in the body, such as in the peritoneal cavity. These disease processes and wounding events potentiate the inflammatory response by activating inflammatory and endothelial cells in local and remote vascular compartments. Within the peritoneal cavity, adjacent visceral elements, such as the omentum and surrounding loops of bowel, become adherent to sites of early inflammation and fibrin matrix degradation to assist in tissue coverage and the delivery of additional inflammatory and cellular mediators of tissue repair.

There is minimal inflammation, fibroplasia or neovascularization in fetal tissue repair. This may be related to the fact that cytokine ratios and the extracellular matrix composition are altered. Fetal wounds are rich in hyaluronic acid, which persists in the wound for several weeks, throughout the course of healing. This is unlike the case for adult wounds in which the hyaluronic acid level peaks at three days, and decreases to zero in seven days. As fetal growth

and differentiation nears completion at the end of gestation. hyaluronic acid levels decline. and wound healing takes on the characteristics of adult wound healing. The prolonged presence of hyaluronic acid in the matrix of fetal wounds is thought to promote fetal fibroblast movement and proliferation. while inhibiting cyto-differentiation. The modified hyaluronic acid composition of this invention may be biologically active. and thereby contribute to the reduction in the observed neovascularization experienced with its use.

The effect of hyaluronic acid on angiogenesis may depends on its molecular weight. High molecular weight hyaluronic acid is believed to inhibit blood vessel formation and be implicated in the differentiation and migration of many cell types. Conversely, low molecular weight hyaluronic acid. including degradation products of HA. such as oligosaccharides of 3 to 10 disaccharide units in length. may stimulate angiogenesis. HA oligosaccharides may act on endothelial cells *in vitro*, and stimulate cell proliferation and migration. two key elements associated with the formation of capillary sprouts.

Hyaluronic acid binds to certain cell surface receptors. such as CD44. RHAMM (Receptor for Hyaluronan Mediated Motility) and ICAM-1 (Intracellular Adhesion Molecule-1). CD44 is widely distributed throughout the body and is recognized as the major cell surface receptor for hyaluronic acid. HA-CD44 binding may be implicated in cell-cell and cell-substrate adhesion, cell migration, proliferation. and activation. as well as HA uptake and degradation. Its precise role in the peritoneum is unknown. The expression of RHAMM on cell surfaces is associated with cell locomotion. ICAM-1 is a cell adhesion molecule widely distributed on endothelial cells. macrophages. and other cells. The binding of HA to ICAM-1 is thought to influence endothelial cell-leukocyte binding. and thus to contribute to the control of ICAM-1 mediated inflammatory activation.

From the above description. one skilled in the art can easily ascertain the essential characteristics of the present invention. and without departing from the spirit and scope thereof. can make various changes and modifications of the invention to adapt it to various usages and conditions.

As one skilled in the art will appreciate. gels and films of the invention can be made using protocols that are within the method of the invention yet are different in particulars from those described here.

The following example is provided by way of illustration and is not intended to limit the invention except as set forth in the appended claims.

## EXAMPLE

This example compares and contrasts the effects of Seprafilm and a control on the growth of vessels and the formation of adhesions.

5        88 C57BL6/J Nonagouti (black) mice, between 6 and 8 weeks old, weighing approximately 22 grams at the time of the procedure, were obtained, and a permanent black mark was used on their tails to identify the animals. Only healthy animals, previously unused in experimental procedures, were used in this experiment.

10       The animals were acclimated for a minimum of 24 hours prior to the experiment. Only animals that appeared normal (healthy appetite, bright clear eyes, no unusual exudate from any body orifice, alert and active posture) were subjected to the experimental procedure.

A maximum of 4 animals were housed in polycarbonate 7 x 11 x 5 inch cages. A maximum number of 10 animals were housed in each polycarbonate 10 x 19 x 6 inch large cage. The room temperature was maintained at 74°F to 76°F with 40% to 50% relative  
15       humidity, and a light/dark cycle of 12 hours/12 hours.

Food and tap water were provided *ad libitum*. Feed and water supplies may have had some contaminants, but that should not have had the potential to influence the outcome of the experiment. The experiment was performed in accordance with NIH guidelines as described in the Guide for the Care and Use of Laboratory Animals, *National Academy Press* (1996).

20       The mice were randomly separated to serve either as surgical controls (N=44 with n=16 in each group, except day 35, n=12), or receive Seprafilm (N=44 with n=16 in each group, except day 35, n=12). The mice were randomly assigned to be sacrificed on post-operative days 10, 15 and 35.

The mice were fasted for 6 hours prior to surgery. Sterile surgical procedures were  
25       performed using an operative Zeiss OPMI 7 microscope fitted with a 200-mm focal length lens. General anesthesia was provided with an isoflurane chamber. A rodent inhalation anesthesia machine was used. The individual animal was first placed in the chamber with an oxygen and isoflurane mixture (3L O<sub>2</sub> and 3L Isoflurane), then, upon induction, the animal was weighed and transferred to an animal mount, and connected to an anesthesia machine for  
30       continued anesthesia. The level of anesthesia was monitored by assessing the animal's vital signs, including heart rate, and spontaneous respiratory rate. The oxygen/isoflurane gas mixture flowed at approximately 1.5 L/min.

All four limbs of the animal were restrained with tape during surgery. The abdomen was shaved, cleansed with Betadine, and sterilely draped. An approximate 2.0-cm midline incision was made, and the abdominal wall everted so as to expose the left side of the peritoneal cavity. A 5 mm x 5 mm x 0.2 mm square piece of sterile polymeric silicone (Dow Corning Corporation, Medical Products, Midland, Michigan, USA) was fixed posterior and lateral to the left epigastric artery and vein using two separate corner stitches of 8/0 Nylon. A cecal abrasion was created by stroking the anterior and posterior walls of the cecum 20 times each with sterile gauze. An adjacent peritoneal injury was created by clamping the sidewall of the peritoneal cavity for 30 seconds with a hemostat. Treatment animals underwent placement of three 1 cm<sup>2</sup> pieces of Seprafilm (Genzyme Corporation, Cambridge, Massachusetts, USA) as follows: 1 piece was placed between the silastic patch and overlying bowel, 1 piece was wrapped around the cecum to cover the cecal abrasions, and 1 piece was placed on top of the bowel beneath the midline laparotomy incision. The peritoneal cavity was open for approximately 20 minutes per animal. The midline incision was closed with a single layer of interrupted 6/0 Nylon. A subcutaneous injection of 2 mg/kg of buprenorphine HCl (Buprenex™) was then given for management of postoperative pain.

The animals were allowed to recover, and their breathing pattern and state of alertness were observed by both the surgeon and assistant. Once the animal was fully awake, breathing in a normal pattern and ambulatory, it was returned to a new cage where food and drink were given *ad libitum*. During the postoperative period, the surgeon and assistant observed the mice daily, assessing each animal's breathing pattern, state of alertness, corneal clarity, food and liquid intake, as well as any signs of distress.

Both control and treatment animals were given subcutaneous injections of normal saline every other day for 10 days post surgery. There were a total of 88 animals, with n=16 in every group, except for day 35 with n=12. One animal from the day 35, Seprafilm group developed peritonitis, was euthanized and excluded from data analysis. All other animals are included in the results herein.

Animals from both groups were sacrificed on post-operative days 10, 15, and 35. Prior to sacrifice, the animals were weighed, shaved and their skin prepared with Betadine. The same method of anesthesia was used as above for the initial procedure. The abdomen was opened through a right paramedian incision, and the right side of the peritoneal cavity was swabbed for culture onto blood agar plates (Remel Microbiology), and incubated for 48 hours

at 37°C. Both sides of the abdomen were carefully inspected for the presence of adhesions. The adhesions were scored based on extent, type and tenacity (see below). The abdominal wall and silastic patch were transilluminated, and photographs of the patch and any associated adhesions were taken with a 35mm camera attached to the Zeiss microscope (see below). The patch was excised along with any associated adhesions, and preserved in 10% neutral buffered formalin. Spleen weights were taken at the time of sacrifice. Urine and serum samples were taken at sacrifice and stored at -80°C and -20°C, respectively. Animals were then euthanized in a precharged CO<sub>2</sub> environment.

At the time of sacrifice the adhesions were assessed and scored. During sacrifice, the abdominal wall was everted and the silicone patch transilluminated using a custom-designed platform. This provided a clear image of the patch without light reflection for optimal imaging purposes. Photographs of the silastic patch and any associated adhesions were obtained using a 35mm camera attached to the Zeiss microscope. A reticle was placed on the tissue adjacent to the patch. All measurements were standardized against the 0.1mm grid of the reticle. Photographic slides of the images were digitized and analyzed using the computer UTHSCSA *ImageTool* program (developed at the University of Texas Health Science Center at San Antonio, Texas and available from the Internet by anonymous FTP from maxrad6.uthscsa.edu).

The digitized images were used to calculate the percent of vascularized peritoneum over the patch. This was calculated by measuring the extent of vascularized peritoneum per area of patch not covered by an adhesion. If there was no adhesion present, the extent of vascularized peritoneum was measured per area of patch. The area under any associated adhesions was not considered in the calculation. This was done so as not to presume that vessels were present under the entire adhesion, nor to disturb the adhesions before histological analysis.

Adhesions were evaluated by carefully lifting the sides of the abdominal wall adjacent to where the silastic patch and cecal abrasions were located. The adhesions were scored using the classification contained in Bigatti, *Human Reproduction*, 10, pages 2290-2294, (1995), based on extent, type and tenacity, as shown in Table 1. The total adhesion score was calculated from the sum of the extent, type and tenacity scores for the adhesions to the silastic patch and cecal abrasion.

TABLE 1

	<u>Characteristic</u>	<u>Adhesion Score</u>
	TENACITY	
5	None	0
	Adhesions essentially fell apart	1
	Adhesions lysed with traction	2
	Adhesions required sharp dissection	3
10		
	TYPE	
	None	0
15	Filmy. no vessels (transparent)	1
	Dense. no vessels (translucent)	2
	Dense. vascular. small vessels (diameter <50 $\mu$ m)	3
	Dense. vascular. large vessels (diameter 50-110 $\mu$ m)	4
20		
	EXTENT	
	(% of silastic patch surface covered by adhesions)	
	0	0
	<25	1
25	25-50	2
	50-75	3
	>75	4

30 During the evaluation and scoring of adhesions, more than one visceral adhesion to the silastic patch in either the control or Seprafilm group was not detected. For example, in the day 10 control group, 10 of 12 adhesions were a single omental adhesion to the patch, 1 was a cecal adhesion, 1 was a bladder adhesion, and 4 animals had no adhesions, as shown in Table 2.

TABLE 2

	Day 10	Day 15	Day 35
Control:			
Omentum	10/16	15/16	9/12
Other*	2/16	0/16	1/12
No Adhesions	4/16	1/16	1/12
Seprafilm:			
Omentum	6/16	2/16	1/11
Other*	1/16	1/16	0/11
No Adhesions	9/16	13/16	11/11

\*Other: Bladder. Bowel. Cecum or Liver

5

Adhesions associated with the cecal abrasions tended to be more complex and composed of multiple visceral elements, especially in the control animals, as shown in Table 3. In the Seprafilm cecal abrasion groups, the adhesions were less complex and commonly composed of multiple visceral elements.

10

TABLE 3

	Day 10	Day 15	Day 35
Control:			
Omentum	6/16	4/16	10/12
Peritoneal Sidewall	2/16	1/16	0/12
Other*	6/16	12/16	9/12
No Adhesions	8/16	8/16	2/12
Seprafilm:			
Omentum	11/16	10/16	7/11
Peritoneal Sidewall	0/16	0/16	0/11
Other	3/16	2/16	3/11
No Adhesions	5/16	6/16	2/11

\*Other: Bladder. Bowel. Mesentery. Cecum. Silastic Patch or Button.

15

The patch adhesion scores were obtained by summing the extent, type and tenacity scores. On average, the total adhesion score was essentially a measure of the extent of adhesion formation since the majority (90%) of the adhesions required sharp dissection (tenacity=3). These adhesions also had dense, vascular, large vessels (type=4). As a result, adhesion scores varied as the extent of the adhesion coverage over the patch varied. In control

animals. the average total adhesion scores were 6.6 at day 10 (SE=1.2, n=16), 8.8 at day 15 (SE=0.7, n=16), and 8.3 at day 35 (SE=1.1, n=16). In the Septrafilm animals, the average total adhesion scores were significantly less compared with the control animals and decreased over time. The total adhesion scores for the Septrafilm animals were 3.5 at day 10 (SE=1.1, n=16), 1.1 at day 15 (SE=0.6, n=16), and 1.0 at day 35 (SE=1.0, n=11). This is shown graphically in Figure 1.

The frequency of adhesion formation in control and treatment animals is summarized in Table 4 and represented graphically in Figure 2. In control animals, the incidence of adhesions was 75% at day 10 (n=16), 94% at day 15 (n=16), and 83% at day 35 (n=12). In Septrafilm animals, the incidence of adhesions decreased over time, from 44% at day 10 (n=16), to 19% at day 15 (n=16), and 9% at day 35 (n=11). The incidence of adhesion formation in the treated animals was significantly less when compared to the control animals at day 15,  $p<0.001$ , and at day 35,  $p=.001$ .

15

TABLE 4

Total N*	# of animals lost from analysis**	Day 10	Day 15	Day 35
44	0	12/16	15/16	10/12
44	1	7/16	3/16	1/11
			$p<0.001$	$p=.001$

n=16 in each group except day 35 n=12

is; animal euthanized

s, n=16 in each group except day 35, n=11

Angiogenesis was evaluated by measuring the area of vascularized peritoneum over the silastic patch in control and Septrafilm animals at days 10, 15 and 35, as shown graphically in Figure 3. In the day 10 Septrafilm animals, vascular ingrowth over the patch was significantly less than in day 10 control animals (32%, SE=7.1, n=16 versus 64%, SE=8.9, n=16,  $p=.02$ ). Thereafter, there was rapid vessel ingrowth over the patch in the

20

Seprafilm animals, such that on days 15 and 35, there was no significant difference in vessel coverage over the patch.

To discern whether vessel ingrowth over the patch in day 10 control and Seprafilm animals may be influenced by the presence or absence of adhesions, we further stratified the day 10 animals, as shown in Table 5. In the groups without adhesions, there was less vascular coverage in the Seprafilm treated animals, suggesting that Seprafilm delayed vessel ingrowth over the silastic patch. When we looked at those animals with adhesions, the percent vascular coverage was again less in the Seprafilm animals compared with the control group. Because of the small sample sizes, it is not possible to ascribe the inhibition of vessel coverage over the silastic patch in the day 10 Seprafilm animals to a direct anti-angiogenic or pure barrier effect. Instead, our results suggest that Seprafilm has a dual effect, with perhaps the barrier effect being greater than the inhibitory effect on endothelial cell growth.

TABLE 5

	All Animals (N=32)	Animals with Adhesions (N=19)	Animals without Adhesions (N=13)
Control	64% (n=16)	74% (n=12)	31% (n=4)
Seprafilm	32% (n=16)	43% (n=7)	23% (n=9)
p-value	p=.02	p=.091	p=0.6993


## CLAIMS

1. A method for inhibiting angiogenesis in a mammal comprising locally administering  
5 to the site of tumor formation or inflammation in said mammal an effective angiogenesis  
inhibiting amount of a pharmaceutical preparation comprising the reaction product of a  
polyanionic polysaccharide and an activating agent or crosslinking agent.
2. The method of claim 1 wherein the mammal is a human.
3. The method of claim 2 wherein the pharmaceutical preparation is administered to a  
10 solid tumor and surrounding tissue in said human.
4. The method of claim 3 wherein the tumor is a cancerous tumor.
5. The method of claim 2 wherein the pharmaceutical preparation is administered to the  
site of inflammation in said human.
6. The method of claim 5 wherein the inflammatory condition is selected from the group  
15 consisting of rheumatoid arthritis, psoriasis, pyogenic granuloma, scleroderma, trachoma,  
endometriosis, arteriosclerosis, intimal hyperplasia, proliferative retinopathy, and the like.
7. The method of claim 1 wherein the pharmaceutical preparation also reduces the  
formation of surgical adhesions.
8. The method of claim 1 wherein the polyanionic polysaccharide is selected from the  
20 group consisting of hyaluronic acid, carboxymethylcellulose, carboxymethylamylose,  
chondroitin sulfate, dermatin sulfate, heparin, and heparin sulfate.
9. The method of claim 8 wherein the polyanionic polysaccharide is hyaluronic acid.
10. The method of claim 8 wherein said polyanionic polysaccharide is  
25 carboxymethylcellulose.
11. The method of claim 1 wherein the polyanionic polysaccharide comprises, in  
combination, two or more different polyanionic polysaccharides.

12. The method of claim 1 wherein one of the polyanionic polysaccharides hyaluronic acid, and the other polyanionic polysaccharide is carboxymethylcellulose.
13. The method of claims 1, 9 or 12 wherein the activating agent is a carbodiimide.
14. The method of claim 13 wherein said carbodiimide comprises 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide methiodide.
15. The method of claim 13 wherein the reaction is carried out in an aqueous medium at a pH of from about 3.5 - 8.0.
16. The method of claim 13 wherein the polyanionic polysaccharide is present in a concentration of 0.005-0.1M.
17. The method of claim 16 wherein the polyanionic polysaccharide is present in a concentration of 0.01-0.02M.
18. The method of claim 13 wherein the molar ratio of the polyanionic polysaccharide to the activating agent is at least 1:1.
19. The method of claim 18 wherein the molar ratio of the polyanionic polysaccharide to the activating agent is about 1:4.
20. The method of claim 1 wherein the crosslinking agent is divinyl sulfone.
21. The method of claim 1 wherein the pharmaceutical preparation is administered to the patient using a minimally invasive or open surgical procedure.
22. The method of claim 1 wherein the pharmaceutical preparation is in the form of a film.
23. The method of claims 1 or 21 wherein the pharmaceutical preparation is in the form of a gel.
24. The method of claim 1 wherein the pharmaceutical preparation is water insoluble.
25. The method of claim 1 wherein the pharmaceutical preparation includes a pharmaceutically active substance dispersed within the preparation.

26. The composition of claim 25 wherein said pharmaceutically active substance is a chosen from the group consisting of proteins, growth factors, soluble receptors, antibodies, enzymes, drugs, biopolymers, and biologically compatible synthetic polymers.
27. The pharmaceutical preparation of claim 26 wherein the pharmaceutically active  
5 substance is a steroid.
28. The method of claim 1 wherein the local administration of the pharmaceutical preparation is performed in conjunction with chemotherapy to treat a cancer patient.
29. A method for inhibiting angiogenesis in a mammal comprising locally administering to the site of tumor formation in said mammal an angiogenesis inhibiting amount of a  
10 pharmaceutical preparation comprising the reaction product of hyaluronic acid, carboxymethylcellulose, and a carbodiimide.
30. The method of claim 29 wherein the pharmaceutical preparation is in the form of a film.
31. The method of claim 29 wherein the pharmaceutical preparation is in the form of a gel.

1/3




Day 10,  $P = 0.4$

Day 15,  $P < .0001$


Day 35,  $P = .0002$

**FIG. 1**

2/3

Day 15,  $P < .0001$ Day 35,  $P = .0001$ **FIG. 2**

3/3



Day 10,  $P = .02$

Day 15,  $P = .09$

Day 35,  $P = 0.15$

**FIG. 3**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 September 2000 (21.09.2000)

PCT

(10) International Publication Number  
**WO 00/54762 A3**

(51) International Patent Classification<sup>7</sup>: A61K 31/728,  
A61P 41/00, 29/02, 35/00

(21) International Application Number: PCT/US00/06819

(22) International Filing Date: 15 March 2000 (15.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/124,703 15 March 1999 (15.03.1999) US

(71) Applicant (*for all designated States except US*):  
TRUSTEES OF BOSTON UNIVERSITY [US/US]; 147  
Bay State Road, Boston, MA 02215 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): MOULTON, Steven  
[US/US]; 217 Westerly Road, Weston, MA 02193 (US).

(74) Agent: GOSZ, William, G.; Wolf, Greenfield & Sacks,  
P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DZ,  
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,  
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,  
UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *With international search report.*

(88) Date of publication of the international search report:  
8 March 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF CROSS LINKED POLYSACCHARIDES FOR THE INHIBITION OF ANGIOGENESIS

(57) Abstract: Angiogenesis is inhibited by the local administration of a pharmaceutical preparation formed from the reaction of hyaluronic acid, carboxymethylcellulose and a carbodiimide. The preparation, which can be in the form of a film or a gel, is advantageously applied directly to the site of a tumor, such as a cancerous tumor, used in conjunction with other chemotherapeutic techniques, or used to treat a chronic inflammatory condition, such as rheumatoid arthritis, endometriosis, arteriosclerosis, intimal hyperplasia, proliferative retinopathy, and the like.

WO 00/54762 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/06819

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/728 A61P41/00 A61P29/02 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92 20349 A (GENZYME CORP) 26 November 1992 (1992-11-26)  page 30, line 24-30 examples 19,21,22 claims 75-91  ---	1,2,4,8, 9,11,13, 14,29-31
X	WO 92 00105 A (GENZYME CORP) 9 January 1992 (1992-01-09)  page 17, line 9-25; claims; example 1  ---	1,2,4,8, 9,11,13, 14,29-31
X	EP 0 507 604 A (ETHICON INC) 7 October 1992 (1992-10-07)  the whole document  ---	1,2,7,8
Y		1-31
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 October 2000

Date of mailing of the international search report

21/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

# INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/US 00/06819

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DHED R ET AL: "EARLY-RESPONSE GENE SIGNALLING IS INDUCED BY ANGIOGENIC OLIGOSACCHARIDES OF HYALURONAN IN ENDOTHELIAL CELLS, INHIBITION BY NON-ANGIOGENIC, HIGH-MOLECULAR-WEIGHT HYALURONAN" INTERNATIONAL JOURNAL OF CANCER, US, NEW YORK, NY, vol. 71, 1997, pages 251-256, XP002922065 ISSN: 0020-7136 figures 1,4-6 ---	1-31
Y	US 5 847 002 A (FALK RUDOLF EDGAR ET AL) 8 December 1998 (1998-12-08) cited in the application the whole document ---	1-31
Y	US 5 866 554 A (SHALABY SHALABY W ET AL) 2 February 1999 (1999-02-02) the whole document ---	1-31
Y	WO 97 40841 A (HYAL PHARMA CORP ;FALK RUDOLF EDGAR (CA)) 6 November 1997 (1997-11-06) the whole document ---	1-31
Y	WO 96 05845 A (TURLEY EVA ANNE ;ASCULAI SAMUEL SIMON (CA); HYAL PHARMA CORP (CA)) 29 February 1996 (1996-02-29) page 2, line 20-37 -----	1-31

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

The definitions "polyanionic polysaccharide", "activating agent" and "crosslinking agent" relate to a rather elevated number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found only for a very small proportion of the compounds. Also the expression of claim 6: "and the like" is considered obscure. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole scope of the claims is impossible.

Also the definition "method for inhibiting angiogenesis" is considered obscure, not defining a specific disease recognized in the art to which the invention belongs.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the use of the cross linked polymers mentioned in claim 8 crosslinked with the carbodiimide compounds of claim 14, with particular emphasis on Seprafilm TM used in the examples, in relation to the treatment of surgical adhesion, tumours, inflammation and the disorders in claim 6, with due regard to the general idea underlying the application.

Note also that claim 12 should depend from claim 11.

Searched partially: claims 1-31

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

... Information on patent family members

Internat'l Application No

PCT/US 00/06819

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9220349 A	26-11-1992	AU 670030 B AU 2143492 A AU 5226796 A EP 0587715 A JP 6508169 T US 5760200 A US 6030958 A US 5527893 A	04-07-1996 30-12-1992 01-08-1996 23-03-1994 14-09-1994 02-06-1998 29-02-2000 18-06-1996
WO 9200105 A	09-01-1992	US 5017229 A AT 151294 T AU 660282 B AU 8392491 A DE 69125609 D DE 69125609 T DK 537292 T EP 0537292 A ES 2100954 T FI 925802 A GR 3023436 T NO 924875 A US 5760200 A US 6030958 A US 5527893 A	21-05-1991 15-04-1997 22-06-1995 23-01-1992 15-05-1997 17-07-1997 04-08-1997 21-04-1993 01-07-1997 21-12-1992 29-08-1997 16-12-1992 02-06-1998 29-02-2000 18-06-1996
EP 0507604 A	07-10-1992	AU 647905 B AU 1401592 A BR 9201215 A CA 2065111 A GR 92100122 A JP 2702641 B JP 5124968 A US 5532221 A	31-03-1994 08-10-1992 01-12-1992 06-10-1992 16-03-1993 21-01-1998 21-05-1993 02-07-1996
US 5847002 A	08-12-1998	CA 2094203 A AU 694113 B AU 6561694 A AU 6994198 A BR 9405781 A WO 9423725 A CZ 9502679 A EP 0695187 A FI 954914 A HU 74462 A HU 9500653 A IL 109293 A JP 8508505 T NO 954073 A PL 306806 A SG 48924 A SK 126595 A ZA 9402597 A	17-10-1994 16-07-1998 08-11-1994 23-07-1998 16-01-1996 27-10-1994 16-10-1996 07-02-1996 06-11-1995 30-12-1996 28-11-1995 26-01-1999 10-09-1996 04-12-1995 18-04-1995 18-05-1998 05-03-1997 08-02-1995
US 5866554 A	02-02-1999	US 6034148 A US 6037331 A	07-03-2000 14-03-2000
WO 9740841 A	06-11-1997	CA 2175282 A AU 2564497 A	30-10-1997 19-11-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/06819

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9605845 A	29-02-1996	CA 2130762 A	25-02-1996
		US 5674857 A	07-10-1997
		AP 619 A	10-10-1997
		AU 701014 B	21-01-1999
		AU 3107095 A	14-03-1996
		CN 1131539 A	25-09-1996
		EP 0777487 A	11-06-1997
		HU 76895 A	29-12-1997
		JP 10506884 T	07-07-1998
		US 5767106 A	16-06-1998
		ZA 9507056 A	26-03-1996

---

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**